Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$2.26
Day's Change
-0.2067 (-8.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.31
Day's Low
2.16
Volume
(Heavy Day)

Today's volume of 168,991 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.

168,991
Historical quotes & splits

Maxar shares soar premarket on report of takeover by Advent

7:09 am ET December 16, 2022 (MarketWatch)
Print

By Colin Kellaher

Shares of Maxar Technologies Inc. took flight in premarket trading Friday after The Wall Street Journal reported that private-equity firm Advent International has agreed to buy the satellite owner and operator at a more than 100% premium.

Advent will pay $53 a share for Maxar, executives at the private-equity firm told the Journal, more than double Thursday's closing price of $23.10 for the Westminster, Colo., company.

The deal is worth about $4 billion, or roughly $6.4 billion including debt, and is slated to be announced later Friday.

Maxar shares (MAXR) were recently up to $50.16 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

-Colin Kellaher

(END) Dow Jones Newswires

December 16, 2022 07:09 ET (12:09 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.

3rd Party Research Disclosure